2-chloro-4-(3,6-dihydro-2H-pyran-4-yl)-thieno[3,2-d]pyrimidine | 1174766-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2-chloro-4-(3,6-dihydro-2H-pyran-4-yl)-thieno[3,2-d]pyrimidine
• 英文别名: 2-chloro-4-(3,6-dihydro-2H-pyran-4-yl)thieno[3,2-d]pyrimidine
• CAS: 1174766-32-5
• 化学式: C₁₁H₉ClN₂OS
• 分子量: 252.724
• InChiKey: IFGKHZJAKPNWAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  63.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-chloro-4-(3,6-dihydro-2H-pyran-4-yl)-thieno[3,2-d]pyrimidine 、 4-氨基苯硼酸频哪醇酯 在 四(三苯基膦)钯 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 4-(4-(3,6-dihydro-2H-pyran-4-yl)thieno[3,2-d]pyrimidin-2-yl)aniline
  参考文献：
  名称：

  Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)

  摘要：

  The morpholine hinge-region binding group on a series of pyrazolopyrimidine and thienopyrimidine mammalian target of rapamycin ( mTOR) inhibitors was replaced with 3,6-dihydro-2H-pyran (DHP), giving compounds of equivalent potency and selectivity versus PI3K. These results establish the DHP group as a hinge-region binding motif for the preparation of highly potent and selective mTOR inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.050
• 作为产物：
  描述：

  2,4-二氯噻吩并[3,2-D]嘧啶 、 三丁基(3,6-二氢-2H-吡喃-4-基)锡烷 在 氮气 、 双三苯基磷二氯化钯 、 乙酸乙酯 、 hexanes 作用下， 以 四氢呋喃 为溶剂， 反应 4.08h， 以to give 425 mg (1.68 mmol, 74%) of the title compound的产率得到2-chloro-4-(3,6-dihydro-2H-pyran-4-yl)-thieno[3,2-d]pyrimidine
  参考文献：
  名称：

  1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

  摘要：

  本发明涉及1H-吡唑并[3,4-d]嘧啶、嘌呤、7H-嘌呤-8（9H）-酮、3H-[1,2,3]三唑并[4,5-d]嘧啶和噻吩[3,2-d]嘧啶化合物，包括这些化合物的组合物，以及制备和使用这些化合物的方法。

  公开号：

  US20090192176A1

文献信息

• 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
  申请人：Zask Arie

  公开号：US20090192176A1

  公开（公告）日：2009-07-30

  The invention relates to 1H-pyrazolo[3,4-d]pyrimidine, purine, 7H-purin-8(9H)-one, 3H-[1,2,3]triazolo[4,5-d]pyrimidine, and thieno[3,2-d]pyrimidine compounds, compositions comprising the compounds, and methods for making and using the compounds.

  这项发明涉及1H-吡唑并[3,4-d]嘧啶，嘌呤，7H-嘌呤-8(9H)-酮，3H-[1,2,3]三唑并[4,5-d]嘧啶和噻吩[3,2-d]嘧啶化合物，包含这些化合物的组合物，以及制备和使用这些化合物的方法。
• Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
  作者：Joshua Kaplan、Jeroen C. Verheijen、Natasja Brooijmans、Lourdes Toral-Barza、Irwin Hollander、Ker Yu、Arie Zask

  DOI：10.1016/j.bmcl.2009.11.050

  日期：2010.1

  The morpholine hinge-region binding group on a series of pyrazolopyrimidine and thienopyrimidine mammalian target of rapamycin ( mTOR) inhibitors was replaced with 3,6-dihydro-2H-pyran (DHP), giving compounds of equivalent potency and selectivity versus PI3K. These results establish the DHP group as a hinge-region binding motif for the preparation of highly potent and selective mTOR inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.